Login to Your Account



Blockbuster Potential

Algeta's Xofigo Wins FDA Nod Ahead of Schedule

By Catherine Shaffer
Staff Writer

Thursday, May 16, 2013
Algeta ASA and partner Bayer AG disclosed FDA approval Wednesday for Xofigo (radium Ra 223 dichloride) in castration-resistant prostate cancer, with the agency's nod coming three months ahead of the Aug. 14 PDUFA date.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription